High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors.
Seventeen patients were treated with high-dose melphalan with autologous bone marrow transplant (ABMT) and cyclophosphamide pretreatment. All of the patients had marrow reconstitution. Although there was one death caused by infection, high-dose melphalan with ABMT causes toxicity that is generally acceptable, and can achieve a high-response rate, but with responses of short duration in tumors resistant to standard-dose combination chemotherapy. In other poor-prognosis tumors that are sensitive to chemotherapy, or can be debulked surgically, or locally irradiated, high-dose melphalan with ABMT given as late intensification therapy may significantly prolong time to relapse, and ultimately prolong survival.
D000328:Adult; D001424:Bacterial Infections / Q000139:chemically induced; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000139:chemically induced; D009369:Neoplasms / Q000628:therapy*; D011379:Prognosis; D014839:Vomiting / Q000139:chemically induced
D003520:Cyclophosphamide; D008558:Melphalan